Nilotinib usage guide, how to take it

Nilotinib is a drug used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), specifically in patients who have developed resistance or intolerance to previous treatments such as imatinib.

Nilotinib is mainly used to treat adult patients in the chronic phase or accelerated phase of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) who are resistant or intolerant to previous treatments. 2 times a day, 300-400mg each time (if the capsule size is 200mg, then 2 tablets each time), with an interval of about 12 hours. It should be taken at least 1 hour before a meal or at least 2 hours after a meal to ensure optimal absorption of the medication. Capsules should be swallowed whole with water and should not be chewed, sucked or opened. If the capsule is accidentally damaged, avoid inhaling the powder or letting the powder contact the skin or mucous membranes.

There are currently no clinical study data in children or adolescents, so nilotinib is not recommended for the treatment of patients 18 years old. No special dosage adjustments are usually required in patients over 65 years of age. This drug should be contraindicated in patients who are allergic to nilotinib or any excipients, who have hypokalemia, hypomagnesemia, or long QT syndrome.

During use of nilotinib, electrocardiograms should be performed regularly to monitor theQTc interval. If QTcprolongation occurs (such as QTc>480ms), it may be necessary to adjust the dose or suspend the medication, and promptly detect serum potassium and magnesium levels. Low potassium and low magnesium may increase the risk of QT prolongation, so regular monitoring should be done to ensure that these electrolyte levels are within normal limits.

If any adverse reactions, such as hematological toxicity (such as anemia, thrombocytopenia, etc.) occur during the use of nilotinib, you should consult a physician immediately and make adjustments according to the recommendations.

Please be sure to follow the above guidelines and use nilotinib under the guidance of your doctor to ensure the safety and effectiveness of the treatment.